Single-pill combination therapy is the standard of care for hypertension, but it is time for the next step: Implementation
Journal
Med
ISSN
2666-6340
Date Issued
2024-12
Author(s)
Jose P. Lopez-Lopez
Abstract
The GMRx2 trial1 in adults with high blood pressure (BP) demonstrated that after 12 weeks, a low-dose single-pill combination of telmisartan, amlodipine, and indapamide significantly reduced BP levels compared to several dual combinations (telmisartan with amlodipine, telmisartan with indapamide, or amlodipine with indapamide).
Adverse events did not differ between the groups.
This novel therapeutic option could improve high BP control
Adverse events did not differ between the groups.
This novel therapeutic option could improve high BP control